These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36645222)

  • 21. Reversing nonalcoholic fatty liver disease-related cirrhosis by inhibiting pyruvate kinase M2: a role for shikonin?
    Minoretti P; Emanuele E
    J Gastroenterol Hepatol; 2023 Aug; 38(8):1447. PubMed ID: 37354060
    [No Abstract]   [Full Text] [Related]  

  • 22. Nonalcoholic Steatohepatitis: Histopathology Basics Within a Broader Context.
    Schild MH; Guy CD
    Surg Pathol Clin; 2018 Jun; 11(2):267-285. PubMed ID: 29751874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-invasive fibrosis assessment in non-alcoholic fatty liver disease.
    Rios RS; Zheng KI; Targher G; Byrne CD; Zheng MH
    Chin Med J (Engl); 2020 Nov; 133(22):2743-2745. PubMed ID: 32932282
    [No Abstract]   [Full Text] [Related]  

  • 24. Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease.
    Xu N; Xie Q; Li J; Gao Y; Li X
    J Int Med Res; 2020 Feb; 48(2):300060520903667. PubMed ID: 32070159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The interaction between current smoking and hemoglobin on the risk of advanced fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease.
    Enc FY; Ulasoglu C; Bakir A; Yilmaz Y
    Eur J Gastroenterol Hepatol; 2020 May; 32(5):597-600. PubMed ID: 31524771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. For fatty liver diseases, it is time to utilize non-invasive fibrosis tests to predict liver related events rather than just histological stages of hepatic fibrosis!
    Peltekian KM
    Ann Hepatol; 2020; 19(6):583-584. PubMed ID: 32853777
    [No Abstract]   [Full Text] [Related]  

  • 27. Nonalcoholic Fatty Liver Disease: Identifying Patients at Risk of Inflammation or Fibrosis.
    Osayande AS; Kale N
    Am Fam Physician; 2017 Jun; 95(12):796-797. PubMed ID: 28671424
    [No Abstract]   [Full Text] [Related]  

  • 28. Letter to the editor: In patients with established NASH cirrhosis, is there no role of weight reduction in reversing fibrosis?
    Kumar A; Sharma P; Arora A
    Hepatology; 2022 Jul; 76(1):E3-E4. PubMed ID: 35092319
    [No Abstract]   [Full Text] [Related]  

  • 29. Fibrosis-4 Index vs Nonalcoholic Fatty Liver Disease Fibrosis Score in Identifying Advanced Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease: A Meta-Analysis.
    Castellana M; Donghia R; Guerra V; Procino F; Castellana F; Zupo R; Lampignano L; Sardone R; De Pergola G; Romanelli F; Trimboli P; Giannelli G
    Am J Gastroenterol; 2021 Sep; 116(9):1833-1841. PubMed ID: 34160377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis.
    Chang D; Truong E; Mena EA; Pacheco F; Wong M; Guindi M; Todo TT; Noureddin N; Ayoub W; Yang JD; Kim IK; Kohli A; Alkhouri N; Harrison S; Noureddin M
    Hepatology; 2023 Feb; 77(2):546-557. PubMed ID: 35809234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
    Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Artificial Intelligence Improves Pathologist Agreement for Fibrosis Scores in Nonalcoholic Steatohepatitis Patients.
    Soon GST; Liu F; Leow WQ; Wee A; Wei L; Sanyal AJ
    Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1940-1942.e3. PubMed ID: 35697267
    [No Abstract]   [Full Text] [Related]  

  • 33. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
    Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
    J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Evolving Role of Liver Biopsy in Non-alcoholic Fatty Liver Disease.
    Arab JP; Barrera F; Arrese M
    Ann Hepatol; 2018 Oct; 17(6):899-902. PubMed ID: 30600304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Letter to the Editor: Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease.
    Yao M; Lu F
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2697-2698. PubMed ID: 36403729
    [No Abstract]   [Full Text] [Related]  

  • 36. Epoxygenase-Derived Epoxyeicosatrienoic Acid Mediators Are Associated With Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Fibrosis.
    Arvind A; Osganian SA; Sjoquist JA; Corey KE; Simon TG
    Gastroenterology; 2020 Dec; 159(6):2232-2234.e4. PubMed ID: 32768596
    [No Abstract]   [Full Text] [Related]  

  • 37. [Hyperhomocysteinemia--a predictor of inflammatory changes in the liver].
    Zviagintseva TD; Hlushchenko SV
    Lik Sprava; 2014 Nov; (11):154-5. PubMed ID: 25528857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease.
    Yang M; Jiang L; Wang Y; Li X; Zou Z; Han T; Nan Y; Lu F; Zhao J
    J Gastrointestin Liver Dis; 2019 Sep; 28(3):289-296. PubMed ID: 31517325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative.
    Pitisuttithum P; Chan WK; Goh GB; Fan JG; Song MJ; Charatcharoenwitthaya P; Duseja A; Dan YY; Imajo K; Nakajima A; Ho KY; Goh KL; Wong VW; Treeprasertsuk S
    World J Gastroenterol; 2020 May; 26(19):2416-2426. PubMed ID: 32476802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease.
    Kessoku T; Ogawa Y; Yoneda M; Imajo K; Sumida Y; Eguchi Y; Fujii H; Hyogo H; Ono M; Suzuki Y; Kawaguchi T; Chayama K; Tanaka S; Fujimoto K; Anzai K; Saibara T; Sata M; Itoh Y; Nakajima A; Okanoue T;
    World J Gastroenterol; 2014 Aug; 20(29):10108-14. PubMed ID: 25110437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.